Merck KGaA CEO Sees Healthy Growth in All Key Parameters for 2019

The transcript discusses Merck's performance in 2018, highlighting growth in healthcare, life sciences, and performance materials. It covers expectations for the multiple sclerosis drug Mavenclad, regulatory challenges, and contributions from pharma pipeline licensing. The progress of acquiring Versum is detailed, emphasizing the benefits of a combined portfolio. The transcript concludes with growth opportunities in healthcare and life sciences, projecting a challenging year for performance materials but a positive long-term outlook.

Can you explain the importance of the healthcare biopharma pipeline for Merck?

How does Merck plan to leverage its R&D capabilities for future innovations?

What are the expected long-term growth opportunities for Merck's electronic materials business?